$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
How long does resistance to osimertinib last?
2025-10-19 11:44:20
Check Details
The best time to take osimertinib
2025-10-19 11:44:20
Check Details
The latest data confirms the significant clinical benefit of entrectinib in the treatment of ROS1 fusion non-small cell lung cancer_ Kanghule
2025-10-19 11:44:20
Check Details
Inventory of targeted therapies for early treatment of non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Safety dosing study of twice-daily pozitinib monotherapy in NSCLC_ Kanghule
2025-10-19 11:44:20
Check Details
Instructions for Icotinib
2025-10-19 11:44:20
Check Details
Which generation of targeted drug is icotinib?
2025-10-19 11:44:20
Check Details
Which company does entrectinib come from?
2025-10-19 11:44:20
Check Details
The role and efficacy of icotinib
2025-10-19 11:44:20
Check Details
Is icotinib included in medical insurance?
2025-10-19 11:44:20
Check Details
How to take entrectinib?
2025-10-19 11:44:20
Check Details
Instructions for Afatinib
2025-10-19 11:44:20
Check Details
1
2
...
3859
3860
3861
3862
3863
3864
3865
...
4163
4164
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Sotorasib (Lumakras): Indications, Dosing, Safety and the Next-Gen KRAS G12C Landscape
2
Weight Gain and Edema Management, Monitoring of Repotrectinib (Augtyro) During Treatment
3
How to Take Tucatinib (Tukysa): Dosing Schedule, Combination Use & Missed Dose Guidance
4
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
5
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
6
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
7
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
8
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
9
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits
10
Erdafitinib in Lung Squamous Cell Carcinoma: Indication Boundaries and FGFR Interpretation
11
Daraxonrasib (Rasonque): Chemical Identity and RAS Tri-Complex Mechanism
12
Tamoxifen and Feeling Older: Managing Hot Flashes, Fatigue, and Skin Changes